The effect of levodopa treatment on vascular endothelial function in Parkinson’s disease
Objective There has been increasing awareness that micro-vascular alteration or vascular inflammation has been associated with levodopa-induced dyskinesia in PD. Vascular endothelial function assessed by flow mediated dilation (FMD) is known to reflect early microvascular change. We compare the impa...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology 2023-06, Vol.270 (6), p.2964-2968 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2968 |
|---|---|
| container_issue | 6 |
| container_start_page | 2964 |
| container_title | Journal of neurology |
| container_volume | 270 |
| creator | Kim, Min Seung Park, Don Gueu Gil, Young Eun Shin, In Ja Yoon, Jung Han |
| description | Objective
There has been increasing awareness that micro-vascular alteration or vascular inflammation has been associated with levodopa-induced dyskinesia in PD. Vascular endothelial function assessed by flow mediated dilation (FMD) is known to reflect early microvascular change. We compare the impact of levodopa or dopamine agonist treatment on the change of FMD in de novo PD patients.
Methods
This retrospective study used a selected sample from registry. We identified de-novo PD patients who underwent FMD at baseline, and follow-up FMD after 1 year (± 2 month) of levodopa (
n
= 18) or dopamine agonist (
n
= 18) treatment.
Results
FMD decreased after levodopa (8.60 ± 0.46 to 7.21 ± 0.4,
p
= 0.002) but there were no significant changes after DA treatment (8.33 ± 0.38 to 8.22 ± 0.33,
p
= 0.26). Homocysteine rose (11.52 ± 0.45 to 14.33 ± 0.68,
p
|
| doi_str_mv | 10.1007/s00415-023-11622-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2777010005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2814154976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-9c934e95fa9f6ae9e392d227f49931577a70bb774cf4a6656185f1bdd259c4c03</originalsourceid><addsrcrecordid>eNp9kLtOHDEUhq2ICBbCC1AgSzQ0kxzfxusSIW4SUlKQhsbyeo7DwKy92DMrpctr5PXyJJgsFylFqiP5_85_rI-QAwafGYD-UgAkUw1w0TDWct7ID2TGpOANk8pskRkICY0SSu6Q3VLuAWBeg22yI1ptQEk1I7c3d0gxBPQjTYEOuE5dWjk6ZnTjEmN9jXTtip8GlynGLo13OPRuoGGKfuxr2kf6zeWHPpYU__z6XWjXF3QFP5GPwQ0F91_mHvl-fnZzetlcf724Oj25brzQamyMN0KiUcGZ0Do0KAzvONdBGiOY0tppWCy0lj5I17aqZXMV2KLruDJeehB75HjTu8rpccIy2mVfPA6Di5imYrnWGqowUBU9-ge9T1OO9XeWz1mVKY1uK8U3lM-plIzBrnK_dPmnZWCfzduNeVvN27_mraxLhy_V02KJ3dvKq-oKiA1QahR_YH6__Z_aJ-Opjs0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2814154976</pqid></control><display><type>article</type><title>The effect of levodopa treatment on vascular endothelial function in Parkinson’s disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kim, Min Seung ; Park, Don Gueu ; Gil, Young Eun ; Shin, In Ja ; Yoon, Jung Han</creator><creatorcontrib>Kim, Min Seung ; Park, Don Gueu ; Gil, Young Eun ; Shin, In Ja ; Yoon, Jung Han</creatorcontrib><description>Objective
There has been increasing awareness that micro-vascular alteration or vascular inflammation has been associated with levodopa-induced dyskinesia in PD. Vascular endothelial function assessed by flow mediated dilation (FMD) is known to reflect early microvascular change. We compare the impact of levodopa or dopamine agonist treatment on the change of FMD in de novo PD patients.
Methods
This retrospective study used a selected sample from registry. We identified de-novo PD patients who underwent FMD at baseline, and follow-up FMD after 1 year (± 2 month) of levodopa (
n
= 18) or dopamine agonist (
n
= 18) treatment.
Results
FMD decreased after levodopa (8.60 ± 0.46 to 7.21 ± 0.4,
p
= 0.002) but there were no significant changes after DA treatment (8.33 ± 0.38 to 8.22 ± 0.33,
p
= 0.26). Homocysteine rose (11.52 ± 0.45 to 14.33 ± 0.68,
p
< 0.05) during levodopa treatment, but dopamine agonist had no effect (10.59 ± 0.38 to 11.38 ± 0.67,
p
= 0.184). Correlation analysis revealed that the changes in homocysteine level had non-significant correlation with FMD change (
r
= − 0.30,
p
= 0.06). FMD change was not associated with age (
p
= 0.47), disease duration (
p
= 0.81), baseline motor UPDRS (
p
= 0.43), motor UPDRS change (
p
= 0.64), levodopa equivalent dose change (
p
= 0.65).
Conclusions
We found that 1-year levodopa treatment may adversely affect vascular endothelial function in de novo PD. Further studies are needed to clarify the exact pathogenesis and clinical implication of levodopa-induced endothelial dysfunction in PD.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-023-11622-4</identifier><identifier>PMID: 36790545</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Agonists ; Antiparkinson Agents - adverse effects ; Correlation analysis ; Dopamine ; Dopamine Agonists - adverse effects ; Dyskinesia ; Homocysteine ; Humans ; Levodopa ; Levodopa - adverse effects ; Medicine ; Medicine & Public Health ; Microvasculature ; Movement disorders ; Neurodegenerative diseases ; Neurology ; Neuroradiology ; Neurosciences ; Original Communication ; Parkinson Disease - complications ; Parkinson's disease ; Patients ; Retrospective Studies</subject><ispartof>Journal of neurology, 2023-06, Vol.270 (6), p.2964-2968</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-9c934e95fa9f6ae9e392d227f49931577a70bb774cf4a6656185f1bdd259c4c03</citedby><cites>FETCH-LOGICAL-c375t-9c934e95fa9f6ae9e392d227f49931577a70bb774cf4a6656185f1bdd259c4c03</cites><orcidid>0000-0001-6180-9848</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-023-11622-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-023-11622-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27915,27916,41479,42548,51310</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36790545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Min Seung</creatorcontrib><creatorcontrib>Park, Don Gueu</creatorcontrib><creatorcontrib>Gil, Young Eun</creatorcontrib><creatorcontrib>Shin, In Ja</creatorcontrib><creatorcontrib>Yoon, Jung Han</creatorcontrib><title>The effect of levodopa treatment on vascular endothelial function in Parkinson’s disease</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>Objective
There has been increasing awareness that micro-vascular alteration or vascular inflammation has been associated with levodopa-induced dyskinesia in PD. Vascular endothelial function assessed by flow mediated dilation (FMD) is known to reflect early microvascular change. We compare the impact of levodopa or dopamine agonist treatment on the change of FMD in de novo PD patients.
Methods
This retrospective study used a selected sample from registry. We identified de-novo PD patients who underwent FMD at baseline, and follow-up FMD after 1 year (± 2 month) of levodopa (
n
= 18) or dopamine agonist (
n
= 18) treatment.
Results
FMD decreased after levodopa (8.60 ± 0.46 to 7.21 ± 0.4,
p
= 0.002) but there were no significant changes after DA treatment (8.33 ± 0.38 to 8.22 ± 0.33,
p
= 0.26). Homocysteine rose (11.52 ± 0.45 to 14.33 ± 0.68,
p
< 0.05) during levodopa treatment, but dopamine agonist had no effect (10.59 ± 0.38 to 11.38 ± 0.67,
p
= 0.184). Correlation analysis revealed that the changes in homocysteine level had non-significant correlation with FMD change (
r
= − 0.30,
p
= 0.06). FMD change was not associated with age (
p
= 0.47), disease duration (
p
= 0.81), baseline motor UPDRS (
p
= 0.43), motor UPDRS change (
p
= 0.64), levodopa equivalent dose change (
p
= 0.65).
Conclusions
We found that 1-year levodopa treatment may adversely affect vascular endothelial function in de novo PD. Further studies are needed to clarify the exact pathogenesis and clinical implication of levodopa-induced endothelial dysfunction in PD.</description><subject>Agonists</subject><subject>Antiparkinson Agents - adverse effects</subject><subject>Correlation analysis</subject><subject>Dopamine</subject><subject>Dopamine Agonists - adverse effects</subject><subject>Dyskinesia</subject><subject>Homocysteine</subject><subject>Humans</subject><subject>Levodopa</subject><subject>Levodopa - adverse effects</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microvasculature</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Original Communication</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Retrospective Studies</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kLtOHDEUhq2ICBbCC1AgSzQ0kxzfxusSIW4SUlKQhsbyeo7DwKy92DMrpctr5PXyJJgsFylFqiP5_85_rI-QAwafGYD-UgAkUw1w0TDWct7ID2TGpOANk8pskRkICY0SSu6Q3VLuAWBeg22yI1ptQEk1I7c3d0gxBPQjTYEOuE5dWjk6ZnTjEmN9jXTtip8GlynGLo13OPRuoGGKfuxr2kf6zeWHPpYU__z6XWjXF3QFP5GPwQ0F91_mHvl-fnZzetlcf724Oj25brzQamyMN0KiUcGZ0Do0KAzvONdBGiOY0tppWCy0lj5I17aqZXMV2KLruDJeehB75HjTu8rpccIy2mVfPA6Di5imYrnWGqowUBU9-ge9T1OO9XeWz1mVKY1uK8U3lM-plIzBrnK_dPmnZWCfzduNeVvN27_mraxLhy_V02KJ3dvKq-oKiA1QahR_YH6__Z_aJ-Opjs0</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Kim, Min Seung</creator><creator>Park, Don Gueu</creator><creator>Gil, Young Eun</creator><creator>Shin, In Ja</creator><creator>Yoon, Jung Han</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6180-9848</orcidid></search><sort><creationdate>20230601</creationdate><title>The effect of levodopa treatment on vascular endothelial function in Parkinson’s disease</title><author>Kim, Min Seung ; Park, Don Gueu ; Gil, Young Eun ; Shin, In Ja ; Yoon, Jung Han</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-9c934e95fa9f6ae9e392d227f49931577a70bb774cf4a6656185f1bdd259c4c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Agonists</topic><topic>Antiparkinson Agents - adverse effects</topic><topic>Correlation analysis</topic><topic>Dopamine</topic><topic>Dopamine Agonists - adverse effects</topic><topic>Dyskinesia</topic><topic>Homocysteine</topic><topic>Humans</topic><topic>Levodopa</topic><topic>Levodopa - adverse effects</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microvasculature</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Original Communication</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Min Seung</creatorcontrib><creatorcontrib>Park, Don Gueu</creatorcontrib><creatorcontrib>Gil, Young Eun</creatorcontrib><creatorcontrib>Shin, In Ja</creatorcontrib><creatorcontrib>Yoon, Jung Han</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Min Seung</au><au>Park, Don Gueu</au><au>Gil, Young Eun</au><au>Shin, In Ja</au><au>Yoon, Jung Han</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of levodopa treatment on vascular endothelial function in Parkinson’s disease</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>270</volume><issue>6</issue><spage>2964</spage><epage>2968</epage><pages>2964-2968</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><abstract>Objective
There has been increasing awareness that micro-vascular alteration or vascular inflammation has been associated with levodopa-induced dyskinesia in PD. Vascular endothelial function assessed by flow mediated dilation (FMD) is known to reflect early microvascular change. We compare the impact of levodopa or dopamine agonist treatment on the change of FMD in de novo PD patients.
Methods
This retrospective study used a selected sample from registry. We identified de-novo PD patients who underwent FMD at baseline, and follow-up FMD after 1 year (± 2 month) of levodopa (
n
= 18) or dopamine agonist (
n
= 18) treatment.
Results
FMD decreased after levodopa (8.60 ± 0.46 to 7.21 ± 0.4,
p
= 0.002) but there were no significant changes after DA treatment (8.33 ± 0.38 to 8.22 ± 0.33,
p
= 0.26). Homocysteine rose (11.52 ± 0.45 to 14.33 ± 0.68,
p
< 0.05) during levodopa treatment, but dopamine agonist had no effect (10.59 ± 0.38 to 11.38 ± 0.67,
p
= 0.184). Correlation analysis revealed that the changes in homocysteine level had non-significant correlation with FMD change (
r
= − 0.30,
p
= 0.06). FMD change was not associated with age (
p
= 0.47), disease duration (
p
= 0.81), baseline motor UPDRS (
p
= 0.43), motor UPDRS change (
p
= 0.64), levodopa equivalent dose change (
p
= 0.65).
Conclusions
We found that 1-year levodopa treatment may adversely affect vascular endothelial function in de novo PD. Further studies are needed to clarify the exact pathogenesis and clinical implication of levodopa-induced endothelial dysfunction in PD.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36790545</pmid><doi>10.1007/s00415-023-11622-4</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-6180-9848</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-5354 |
| ispartof | Journal of neurology, 2023-06, Vol.270 (6), p.2964-2968 |
| issn | 0340-5354 1432-1459 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2777010005 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Agonists Antiparkinson Agents - adverse effects Correlation analysis Dopamine Dopamine Agonists - adverse effects Dyskinesia Homocysteine Humans Levodopa Levodopa - adverse effects Medicine Medicine & Public Health Microvasculature Movement disorders Neurodegenerative diseases Neurology Neuroradiology Neurosciences Original Communication Parkinson Disease - complications Parkinson's disease Patients Retrospective Studies |
| title | The effect of levodopa treatment on vascular endothelial function in Parkinson’s disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T20%3A19%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20levodopa%20treatment%20on%20vascular%20endothelial%20function%20in%20Parkinson%E2%80%99s%20disease&rft.jtitle=Journal%20of%20neurology&rft.au=Kim,%20Min%20Seung&rft.date=2023-06-01&rft.volume=270&rft.issue=6&rft.spage=2964&rft.epage=2968&rft.pages=2964-2968&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-023-11622-4&rft_dat=%3Cproquest_cross%3E2814154976%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2814154976&rft_id=info:pmid/36790545&rfr_iscdi=true |